Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

The effect of different dosage of intranasal dexmedetomidine on preventing emergence delirium or agitation in children: A network meta-analysis of randomized controlled trials

  • Yizheng Li,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliations Department of Anesthesiology, Fujian Medical University Union Hospital, Fuzhou, China, Department of Anesthesiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, China

    ⨯
  • Yi Jiang,

    Roles Investigation

    Affiliation Department of Anesthesiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, China

    ⨯
  • Liangcheng Zhang

    Roles Resources, Supervision, Writing – review & editing

    zlc0567@fjmu.cn

    Affiliation Department of Anesthesiology, Fujian Medical University Union Hospital, Fuzhou, China

    ⨯

Abstract

Background

The clinical evidence for the effects of different doses of intranasal dexmedetomidine on emergence delirium/ emergence agitation (ED/EA) in children is lacking.

Methods

We searched the PubMed, EMBASE and Cochrane Library from the establishment of the databases until December 30, 2023. All randomized controlled trials that evaluated the effect of different dosage of intranasl dexamedetomidine in children younger than 18 years on postoperative ED/ EA were included. Data analysis was conducted using R 4.3.0.

Results

A total of 15 randomized controlled trials involving 1566 children were included. Compared to 0.5 μg/kg (RR = 4.81, 95%CI = 1.66–13.94), and normal saline (RR = 8.23, 95%CI = 4.63–14.65), intranasal dexmedetomidine at doses of 2 μg/kg significantly reduced the incidence of ED/ EA in children. 2 μg/kg was the most effective dosage in reducing the incidence of ED/ EA (Probability of rank = 0.75), the incidence of severe ED/ EA (Probability of rank = 0.45), and ED/ EA score (Probability of rank = 0.65). Moreover, intranasal dexmedetomidine at doses of 2 μg/kg significantly reduced the PACU pain compared to 0.5 μg/kg (RR = 0.42, 95%CI = -0.22–1.06), 1 μg/kg (RR = 0.18, 95%CI = -0.26–0.63), 1.5 μg/kg (RR = 1.00, 95%CI = -0.54–0.75), and normal saline (RR = 8.23, 95%CI = 4.63–14.65), with a probability of rank = 0.45.

Conclusion

2μg/kg intranasal dexmedetomidine is the optimum dose for reducing the occurrence of ED/ EA and postoperative pain. However, further research is required to verify our findings.

Citation: Li Y, Jiang Y, Zhang L (2024) The effect of different dosage of intranasal dexmedetomidine on preventing emergence delirium or agitation in children: A network meta-analysis of randomized controlled trials. PLoS ONE 19(9): e0304796. https://doi.org/10.1371/journal.pone.0304796

Editor: Silvia Fiorelli, Sapienza University of Rome: Universita degli Studi di Roma La Sapienza, ITALY

Received: January 24, 2024; Accepted: May 19, 2024; Published: September 6, 2024

Copyright: © 2024 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Emergence delirium or emergence agitation (ED/ EA) are common postoperative complications in children that characterized by behaviors such as crying, fear, restlessness, and disorientation occurring in the early stages during anesthesia recovery period according to diagnostic criteria of the Pediatric Anesthesia Emergence Delirium (PAED) scale [1]. Meta-analysis by Farag et al. [2] showed the incidence of ED/ EA was 31.4% in pediatric patients underwent sevoflurane anesthesia and surgery. ED/EA in children led to serious consequences such as vomiting, aspiration, laryngospasm, and notably extended hospital stays [3, 4]. Therefore, effective interventions to reduce ED/ EA in pediatrc patients is an issues to be solved.

Dexmedetomidine (DEX), a highly selective α2-adrenoceptor agonist, was a promising medication in this context [5]. Until now, intranasal DEX has been widely used in pediatric patients and showed effectively in reducing the incidence of ED/ EA [6, 7]. Li et al. [8] indicated that children under 3 years, DEX takes sedative and analgesic effect in 20 minutes, maintains a two hour time, and has less effect on systemic vascular and respiratory depression, moreover, intranasal DEX would not induce nasal irritation, making it a suitable option for preoperative medication. However, the dosage of intranasal DEX differed among studies, and the optimal dose for preventing postoperative ED/ EA remains inconclusive.

This network meta-analysis aimed to investigate the optimal dose for preventing postoperative ED/ EA in children, and provided clinical medication guidance.

Methods

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (S1 Table).

Search strategy

We conducted a systematic search in PubMed, Embase, Cochrane Library, and Web of Science databases for studies from the databases esteblished up to December 12, 2023 without restrictions on language. Keywords used were ("Dexmedetomidine") and ("Child" or "Adolescent" or "Pediatrics" or "Youth" or "Teen") and (intranasal) and (“postoperative delirium” or “postoperative agitation” or “emergenc delirium” or “emergenc agitation”). Search strategies were shown in S1 File.

Eligibility criteria

Inclusion criteria were: 1) Children younger than 18 years. 2) American Society of Anesthesiologists (ASA) physical status I-III. 3) DEX group received intranasal DEX as premedication before anesthesia, and control group received normal saline. 4) The incidence of ED/ EA in DEX group and control group both could be converted into dichotomous variable. 5) Randomized controlled trial (RCT). Exclusion criteria were: 1) Other intervention that influenced ED/ EA was used. 2) Letter, abstract.

Data extraction and bias assessment

Two researchers strictly screened the title and abstracts and full texts according to the eligibility criteria, then extracted characteristics of each study, such as authors, publication year, country, age, gender, and sample size. The primary outcome was the incidence of ED/ EA, which was assessed according to Pediatric Anesthesia Emergence Delirium score (PAED), or other delirium and agitation scale. ED/ EA was defined as PEAD score>10 or the equal level as the other grading scale. Secondary outcome included severe ED/ EA which was defined as PEAD score>14 or the equal level as the other grading scale, ED/ EA score, PACU pain score which was assessed according to 1–10 grading scale, parent’s satisfaction which was assesed according to 1–10 grading score, length of PACU stay, postoperative nausea and vomiting, breath holding. Cross-checked were conducted and a third researcher joined the discussion for consensus in cases of disagreement.

The quality assessment of included studies was independently conducted by two researchers using the Cochrane Risk of Bias tool Version 2.0 (RoB2), including five aspects: bias arising from the randomization domains, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, bias in selection of the reported result. Any discrepancies were resolved through consultation with a third reviewer. To assess publication bias, funnel plots was performed and checked its symmetry if articles were more than nine.

Data synthesis and analysis

All the data analyses were performed by R 4.3.0. Odd ratio (OR) with 95% CI was calculated for dichotomous variable, and standard mean difference (SMD) with 95% CI was calculated for continuous variable. Heterogeneity was determined using I2, a random-effects model was employed regardless of heterogeneity.

Network diagram was performed to show the direct and indirect comparison between different dosages, the size of the nodes represents the sample size of each dosage, and the thickness of the lines connecting the nodes indicated the number of studies directly compared between two dosage. When testing global consistency, P>0.05 indicates that there was no overall inconsistency, and the consistency model was used, otherwise non-consistency model was used. League tables were performed to summarize the different dosages of outcomes containing both direct and indirect comparisons. We calculated the probabilities of ranking in all different dosages to rank the effect of different dosages on outcomes.

Results

A total of 159 articles were obtained from the databases, and 17 articles were retained after screening title and abstract. Finally, 15 RCTs with 1566 children were included in this network meta-analysis after full text screening [6, 7, 9–21]. Among these, 13 were from China, 1 was from Egypt, and 1 was from Australian. The investigated treatment arms included 0.5 μg/kg DEX, 1 μg/kg DEX, 1.5 μg/kg DEX, 2.0 μg/kg DEX, and normal saline.

The PRISMA flowchart was shown in Fig 1, The characteristics of included studies was shown in Table 1.

thumbnail
Download:
Fig 1. Flowchart of study screening process.

https://doi.org/10.1371/journal.pone.0304796.g001

thumbnail
Download:
Table 1. Characteristics of included studies on the different dosage of intranasal dexmedetomidine for anti-emergence delirium or agitation.

https://doi.org/10.1371/journal.pone.0304796.t001

Quality risk of bias and publication bias

There were no risk of bias in randomization and deviations from intended interventions in all 15 RCTs. The overall risk was “some concerns” mainly came from not reporting if all patient data was available, as shown in S1 Fig.

Funnel plots of publication bias in the 15 RCTs in all outcomes revealed general symmetry, indicated no signifcant publication bias, as shown in S2 Fig.

Network meta-analysis

Primary outcome.

The incidence of ED/ EA. 13 studies reported the incidence of ED/ EA, 2 μg/kg was the most reported dosage, as shown in network plot in Fig 2A. The consistency model showed no significant inconsistency showed between the direct comparisons and indirect comparisons, as shown in S3 Fig. The network meta analysis revealed that compared to 0.5 μg/kg (RR = 4.81, 95%CI = 1.66–13.94) and normal saline (RR = 8.23, 95%CI = 4.63–14.65), intranasal dexmedetomidine at the doses of 2 μg/kg significantly reduced the incidence of ED/ EA in children, as shown in Fig 3A. 2 μg/kg was the most effective dose in reducing the incidence of ED/ EA (Probability of rank = 0.75), as shown in Fig 4A.

thumbnail
Download:
Fig 2. Network plot diagram for the effect of different intranasal dexmedetomidine dosage on outcomes.

(A) the incidence of emergence delirium or emergence agitation; (B) the incidence of severe emergence delirium or emergence agitation; (C) Score of Pediatric Anesthesia Emergence Delirium Scale; (D) PACU pain VAS score. The thickness of edges and numbers located on the line represent the number of trials for each direct comparison.

https://doi.org/10.1371/journal.pone.0304796.g002

thumbnail
Download:
Fig 3. Network meta-analysis of different intranasal dexmedetomidine dosage on outcomes.

(A) the incidence of emergence delirium or emergence agitation; (B) the incidence of severe emergence delirium or emergence agitation; (C) Score of Pediatric Anesthesia Emergence Delirium Scale; (D) PACU pain VAS score.

https://doi.org/10.1371/journal.pone.0304796.g003

thumbnail
Download:
Fig 4. The probability of ranking plot for the effect of different intranasal dexmedetomidine dosage on outcomes.

(A) the incidence of emergence delirium or emergence agitation; (B) the incidence of severe emergence delirium or emergence agitation; (C) Score of Pediatric Anesthesia Emergence Delirium Scale; (D) PACU pain VAS score.

https://doi.org/10.1371/journal.pone.0304796.g004

Secondary outcome.

Severe ED/ EA. five studies reported the incidence of severe ED/ EA, 1 μg/kg was the most reported dosage, as shown in network plot in Fig 2B. No significant inconsistency showed between the comparisons was shown in S3 Fig. The network meta analysis revealed that compared to 0.5 μg/kg (RR = 8.92, 95%CI = 1.45–45.80) and normal saline (RR = 23.18, 95%CI = 4.34–123.88), intranasal dexmedetomidine at the doses of 2 μg/kg significantly reduced the incidence of ED/ EA in children, as shown in Fig 3B. 2 μg/kg was the most effective dose in reducing the incidence of ED/ EA (Probability of rank = 0.45), as shown in Fig 4B.

ED/ EA score. nine studies reported the ED/ EA score, 2 μg/kg was the most reported dosage, as shown in network plot in Fig 2C. No significant inconsistency showed between the direct comparisons and indirect comparisons, as shown in S3 Fig. The network meta analysis revealed that compared to 1 μg/kg (RR = 0.18, 95%CI = -0.46–0.83), intranasal dexmedetomidine at the doses of 2 μg/kg significantly reduced the incidence of ED/ EA, as shown in Fig 3C. 2 μg/kg was the most effective dose in reducing the incidence of ED/ EA (Probability of rank = 0.65), as shown in Fig 4C.

PACU pain score. six studies reported the PACU pain score, 2 μg/kg was the most reported dosage, as shown in network plot in Fig 2D. No significant inconsistency showed between the direct comparisons and indirect comparisons, as shown in S3 Fig. The network meta analysis revealed that intranasal dexmedetomidine at 2 μg/kg significantly reduced pain compared to 1 μg/kg (RR = 0.18, 95%CI = -0.26–0.63), 1.5 μg/kg (RR = 0.10, 95%CI = -0.54–0.75), and normal saline (RR = 0.57, 95%CI = 0.18–0.95), as shown in Fig 3D. 2 μg/kg was most effective dose in reducing the incidence of ED/ EA (Probability of rank = 0.45), as shown in Fig 4D.

There were four studies each reporting parent’s satisfaction, length of PACU stay, postoperative nausea and vomiting, breath holding. Since limited data, we did not pool these outcomes, as shown in S2 File.

Discussion

Our network meta-analysis found that 2μg/kg preoperative intranasal dexmedetomidine was the most effective doses in reducing the incidence of postoperative ED/ severity of EA, ED/ EA, and ED/ EA score compared with 0.5μg/kg, 1μg/kg, 1.5μg/kg, and normal saline in children. In addition, 2μg/kg was also the most effective in relieving pain in PACU. These findings were helpful for the guidance of clinical medication.

A lot of research supported dexmedetomidine can prevent postoperative delirium. Jen et al. [22] reported that oral dexmedetomidine was effective in reducing sudden agitation in pediatric patients. Dexmedetomidine might prevent ED/ EA in children by promoting NLRP3 inflammasome degradation [23] and reducing hippocampal brain inflammation [24] through the autophagy-ubiquitin pathway, thereby protecting nerves and improving cognitive dysfunction.

At present, only one meta-analysis by Na et al. [25] reported the relationship between intranasal dexmedetomidine and ED/ EA, and concluded that intranasal dexmedetomidine reduced ED/ EA after general anesthesia from 33.2% to 13.6%. This was similar to our findings. However, their study included few studies, mixed drug types in control group, including midazolam, clonidine, ketamine, etc., and no subgroup analysis of different dexmedetomidine dosage, making it unreliability in clinical application. Another meta analysis by Zhou et al. [26] showed that the ED90 of intravenous DEX for preventing EA in pediatric patients undergoing dental surgery with sevoflurane anesthesia was 0.74 μg/kg/h. However, their administration route was intravenous. Our network meta-analysis confirmed the anti-ED/ EA efficacy of dexmedetomidine compared to saline, moreover, we concluded that 2 μg/kg was the optimal dosage via aspects of the incidence, severity, and score of ED/ EA.

We revealed intranasal dexmedetomidine reduced pain in PACU, and 2 μg/kg was the optimal dosage. Fu et al. [27] and Tang et al. [28] showed that intravenous dexmedetomidine reduced postoperative pain in children, which was consistent with ours.

There are some limitations in our study. The number of included studies were small and we did not included non-randomized studies not only for they had lots of confounding factors, but there was no non-randomised study(observational or cohort studies) reporting intranasal dexmedetomidine preventing pediatric patients’ ED/ EA as well. We did not compare the anti-ED/EA effects of different pathways of dexmedetomidine, such as intravenous, oral route. These are needed future studies.

Conclusions

2 μg/kg was the optimal dosage for preventing postoperative ED/ EA and pain. These findings might provided guidance of clinical medication. However, more large-sample, multicenter clinical studies are warranted to further enhance the conclusions.

Acknowledgments

We thank all the researchers in Department of Anesthesiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine.

References

  1. 1. Lerman J, Ingelmo P. Emergence delirium in children: Do the studies reflect reality? Paediatr Anaesth. 2024. pmid:38426641
  2. 2. Farag RS, Spicer AC, Iyer G, Stevens JP, King A, Bain PA, et al. Incidence of emergence agitation in children undergoing sevoflurane anesthesia compared to isoflurane anesthesia: An updated systematic review and meta-analysis. Paediatr Anaesth. 2024;34(4):304–317. pmid:38093624
  3. 3. Park SK, Lim T, Cho H, Yoon HK, Lee HJ, Lee JH, et al. Comparative effectiveness of pharmacological interventions to prevent postoperative delirium: a network meta-analysis. Sci Rep 2021;11:11922. pmid:34099790
  4. 4. Sudhakar G, Aneja J, Gehlawat P, Nebhinani N, Khera D, Singh K. A prospective cohort study of emergence delirium and its clinical correlates in a pediatric intensive care unit in North India. Asian J Psychiatr. 2022;103070. pmid:35339871
  5. 5. Huet O, Gargadennec T, Oilleau JF, Rozec B, Nesseler N, Bouglé A, et al. Prevention of post-operative delirium using an overnight infusion of dexmedetomidine in patients undergoing cardiac surgery: a pragmatic, randomized, double-blind, placebo-controlled trial. Crit Care. 2024;28(1):64. pmid:38419119
  6. 6. He H, Cui Q, Chen H, Huang X, Wang S, Yu T, et al. The Effect of Intranasal Dexmedetomidine on Emergence Delirium Prevention in Pediatric Ambulatory Dental Rehabilitation Under General Anesthesia: A Randomized Clinical Trial. Drug Des Devel Ther. 2023 Nov 30;17:3563–3570. pmid:38054181
  7. 7. Lei DX, Wu CJ, Wu ZY, Wang LY, Zhao Q, She YJ. Efficacy of different doses of intranasal dexmedetomidine in preventing emergence agitation in children with inhalational anaesthesia: A prospective randomised trial. Eur J Anaesthesiol. 2022;39(11):858–867. pmid:36106493
  8. 8. Li BL, Guan YP, Yuen VM, Wei W, Huang M, Zhang MZ, et al. Population Pharmacokinetics of Intranasal Dexmedetomidine in Infants and Young Children. Anesthesiology. 2022;137(2):163–175. pmid:35503980
  9. 9. Shen F, Zhang Q, Xu Y, Wang X, Xia J, Chen C, et al. Effect of Intranasal Dexmedetomidine or Midazolam for Premedication on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomy and Adenoidectomy: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(8):e2225473. pmid:35943745
  10. 10. Yao J, Gong H, Zhao X, Peng Q, Zhao H, Yu S. Parental presence and intranasal dexmedetomidine for the prevention of anxiety during anesthesia induction in children undergoing tonsillectomy and/or adenoidectomy surgery: A randomized controlled trial. Front Pharmacol. 2022;13:1015357. pmid:36601054
  11. 11. Lee-Archer PF, von Ungern-Sternberg BS, Reade M, Betts M, Haenke D, Keys A, et al. The effect of dexmedetomidine on postoperative behaviour change in children: a randomised controlled trial. Anaesthesia. 2020;75(11):1461–1468. pmid:32533791
  12. 12. Yao Y, Sun Y, Lin J, Chen W, Lin Y, Zheng X. Intranasal dexmedetomidine versus oral midazolam premedication to prevent emergence delirium in children undergoing strabismus surgery: A randomised controlled trial. Eur J Anaesthesiol. 2020;37(12):1143–1149. pmid:32976205
  13. 13. Xing Yan, Yuan Xu, Na Lin. Influence of intranasal dexmedetomidine premedication on general anesthesia effect and safety in pediatric patients undergoing monocular fundus examination. Adverse Drug Reactions Journal.2020;22(5):289–294.
  14. 14. Zhang S, Zhang R, Cai M, Zhang K, Zhang M, Zheng J. Intranasal dexmedetomidine premedication in children with recent upper respiratory tract infection undergoing interventional cardiac catheterisation: A randomised controlled trial. Eur J Anaesthesiol. 2020;37(2):85–90. pmid:31644515
  15. 15. Bi Y, Ma Y, Ni J, Wu L. Efficacy of premedication with intranasal dexmedetomidine for removal of inhaled foreign bodies in children by flexible fiberoptic bronchoscopy: a randomized, double-blind, placebo-controlled clinical trial. BMC Anesthesiol. 2019; 19(1):219. pmid:31791239
  16. 16. Ling Gao, Yun Liu, XuDong Yang. The sedative effect of nasal injection of dexmedetomidine before general anesthesia in pediatric oral clinic. Journal of Peking University: Medical Edition, 2018; 50(6):5.
  17. 17. Li LQ, Wang C, Xu HY, Lu HL, Zhang HZ. Effects of different doses of intranasal dexmedetomidine on preoperative sedation and postoperative agitation in pediatric with total intravenous anesthesia undergoing adenoidectomy with or without tonsillectomy. Medicine (Baltimore). 2018;97(39):e12140. pmid:30278489
  18. 18. Ping L I, Gui-Ying G, Dong-Xin W. Clinical trial of intranasal dexmedetomidine premedication reducing early postoperative negative behaviors in children. The Chinese Journal of Clinical Pharmacology, 2018.
  19. 19. Abdelaziz H M M, Bakr R H, Kasem A A. Effect of intranasal dexmedetomidine or intranasal midazolam on prevention of emergence agitation in pediatric strabismus surgery: A randomized controlled study. Egyptian Journal of Anaesthesia, 2016;
  20. 20. Lin Y, Chen Y, Huang J, Chen H, Shen W, Guo W, et al. Efficacy of premedication with intranasal dexmedetomidine on inhalational induction and postoperative emergence agitation in pediatric undergoing cataract surgery with sevoflurane. J Clin Anesth. 2016;33:289–95. pmid:27555179
  21. 21. Yao Y, Qian B, Lin Y, Wu W, Ye H, Chen Y. Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial. Paediatr Anaesth. 2015;25(5):492–8. pmid:25487567
  22. 22. Jen CK, Lu KC, Chen KW, Lu YR, Huang IT, Huang YC, et al. Oral Dexmedetomidine Achieves Superior Effects in Mitigating Emergence Agitation and Demonstrates Comparable Sedative Effects to Oral Midazolam for Pediatric Premedication: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2024;13(4):1174. pmid:38398486
  23. 23. Zhang L, Xiao F, Zhang J, Wang X, Ying J, Wei G, et al. Dexmedetomidine Mitigated NLRP3-Mediated Neuroinflammation via the Ubiquitin-Autophagy Pathway to Improve Perioperative Neurocognitive Disorder in Mice. Front Pharmacol. 2021;12:646265. pmid:34079457
  24. 24. Dumbuya JS, Li S, Liang L, Zeng Q. Paediatric sepsis-associated encephalopathy (SAE): a comprehensive review. Mol Med. 2023;29(1):27. pmid:36823611
  25. 25. Na HS, Kim SY, In Park J, Lee S, Hwang JW, Shin HJ. The effect of intranasal dexmedetomidine administration on emergence agitation or delirium in pediatric patients after general anesthesia: A meta-analysis of randomized controlled trials. Paediatr Anaesth. 2023 (8):636–646. pmid:37128675
  26. 26. Zhou D, Yang XD, Wu HY, Xiong GL, Wang LK. Determination of the ED90 of Dexmedetomidine Infusion to Prevent Emergence Agitation in Children Undergoing Dental Rehabilitation With Sevoflurane Anesthesia: A Biased-Coin Up-and-Down Sequential Allocation Trial. Anesth Analg. 2023; pmid:37478025
  27. 27. Fu Y, Zhang Q, Jiang Y, Lang B. A comparative evaluation of intranasal α2-adrenoceptor agonists and intranasal midazolam as premedication in pediatric sedation: A meta-analysis of randomized controlled trials. PLoS One. 2023;18(2):e0281751. pmid:36787332
  28. 28. Tang Y, Song Y, Tian W, Chen G, Gu Y. A systematic review and meta-analysis on the efficacy and safety of dexmedetomidine combined with sevoflurane anesthesia on emergence agitation in children. Transl Pediatr. 2022;11(7):1156–1170. pmid:35957999